Balyasny Asset Management
TBIO

Balyasny Asset Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Balyasny Asset Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-77,227
Closed -$1.05M – 1846
2020
Q3 		$1.05M Sell
77,227
-273,958
-78% -$4.22M 0.01% 984
2020
Q2 		$6.29M Buy
+351,185
New +$5.3M 0.05% 458

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management's TBIO Position: Q4 2020 in Review

Balyasny Asset Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q4 2020, closing a stake of 77,227 shares — an estimated $1.05M sold.

Balyasny Asset Management first reported a position in TBIO in Q2 2020 and held it in 2 quarters. The position peaked at $6.29M in Q2 2020. 150 funds tracked by Wall St. Rank hold TBIO as of Q4 2020.

  • Balyasny Asset Management reported no remaining Translate Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Balyasny Asset Management sold 77,227 Translate Bio, Inc. Common Stock shares in Q4 2020, an estimated $1.05M.
  • Balyasny Asset Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Balyasny Asset Management's Translate Bio, Inc. Common Stock position peaked at $6.29M in Q2 2020.
  • 150 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q4 2020.

Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.